Table of Content

20 December 2010, Volume 5 Issue 12

Previous Issue    Next Issue

主编手记

The Brightness of a Black Hole

WANG Yong-Jun

2010, 5(12):  955-957. 

Asbtract ( )   PDF (2472KB) ( )  

Related Articles | Metrics

述评

A Focal Point of Cardiovascular and Cerebrovascular Disease: Environmental and Genetic Risk Factors

ZHANG Wei-Li;HUI Ru Tai

2010, 5(12):  959-961. 

Asbtract ( )   PDF (2051KB) ( )  

Related Articles | Metrics

论著

Association Studies on Lymphotoxin-α Polymorphisms and Noncardiogenic Ischemic Stroke in Chinese Han Population

XU Yu-Jun;DING Hu;BAO Xun-Na;et al.

2010, 5(12):  962-966. 

Asbtract ( )   PDF (2515KB) ( )  

Related Articles | Metrics

Objective The aim of the present study was to explore whether genetic polymorphisms oflymphotoxin-alpha (LTA) gene are risk factors for noncardiogenic ischemic stroke in HanChinese population.Methods Three common variants of LTA, rs1800683, rs909253 and rs1041981, were genotypedin a sample including 558 noncardiogenic ischemic stroke cases and 557 normal controls usingTaqman-MGB assay in a case-control study. The association analyses were performed at bothsingle nucleotide polymorphism and haplotype levels. Bonferroni correction was applied formultiple corrections.Results No significant association were found between any of these LTA alleles or genotypeswith risk of noncardiogenic ischemic stroke. When AGA haplotype was chosen as the baseline foradjusting conventional risk factors, the protective effect for haplotype GGC remained significant(AGA versus GGC; OR , 0.381; 95%CI , 0.198 to 0.733; P =0.003).Conclusion The GGC haplotype of LTA maybe a protective factor in pathogenesis ofnoncardiogenic ischemic stroke warrants further confirm in a prospective study.

Mechanism of Ischemic Infarct in Spontaneous Cerebral Arteries Dissection: 28 Cases Report

CHEN Hong-Bing﹡;HONG Hua;LI Ling;et al.

2010, 5(12):  967-973. 

Asbtract ( )   PDF (2794KB) ( )  

Related Articles | Metrics

Objective This study investigated the mechanism of ischemic stroke induced by cerebral arteriesdissection through brain imaging and cerebrovascular findings, and provided evidences for therelative strategies of therapy.Methods Twenty-eight patients with acute ischemic infarct induced by cerebral arteries dissectionconfirmed by clinical and neuroradiological data were recruited. Mechanisms of ischemic infarctwere determined by the infarct lesion morphous and distribution. All patients were divided intothe extracranial group and the intracranial group according to the location of vessel lesions, andthe mechanisms of the two groups were compared.Results Twenty-eight patients (19 males and 9 females) were recruited. There were 17 patientswith extracranial dissection, 15 patients with extracranial internal carotid artery dissection and 2patients with V1 segment dissection of vertebral artery. There were 11 patients with intracranialdissection, 3 patients with M1 segment dissection of middle cerebral artery and 6 patients withV4 segment dissection of vertebral artery and 2 patients with basilar artery dissection. There were7 patients (63.6%) with hypertension and 5 patients (45.5%) with diabetes in the intracranial group,and one patient (5.9%) and one patient (5.9%) respectively in the extracranial group (P valueswere 0.002 and 0.022). There were 12 patients (70.6%) with only thromboembolism infarction inthe extracranial group, 2 patients (18.2%) in the intracranial group (P =0.020). In the intracranialgroup, there were 7 patients (63.6%) with infarction resulted in obstruction of perforatingbranches caused by dissection lesion, and one patient (9.1%) with infarction caused by obstruction of perforating branches and hemodynamic mechanism.Conclusion The mechanisms of ischemic infarct induced by extracranial and intracranialdissection were different. Thromboembolism was the main mechanism of infarct induced byextracranial dissection, and obstruction of perforating branches caused by dissection lesion wasthe main mechanism of infarct induced by intracranial dissection.

Effect of Percutaneous Closure of Patent Foramen Ovale(PFO) or Aspirin Treatment to Ischemic Cerebrovascular Diseases Recurrence of Patients with PFO

GUO Ming;MA Xin;WANG Cai-Rong;et al.

2010, 5(12):  974-978. 

Asbtract ( )   PDF (2540KB) ( )  

Related Articles | Metrics

Objective To observe the effect of percutaneous closure of patent foramen ovale (PFO) or aspirintreatment to ischemic cerebrovascular diseases recurrence of patients with PFO.Methods The resident patients whose age≤55 years with cerebral infarction or transient ischemicattack (TIA) in the department of neurology of XuanWu hospital were selected continuously.All patients were diagnosed by transesophageal echocardiography(TEE). Finally, 45 patientswith PFO were researched. One group treated by aspirin were 38 persons, the other treated bypercutaneous PFO closure were 7. The recurrence rate of ischemic cerebrovascular diseases oftwo groups were compared.Results The size of PFO was not significant difference between two groups(P =0.461). After 3months and 6 months treatment, the group of percutaneous PFO closure had no recurrence, therecurrence rate of the group treated by aspirin were 7.89% and 13.12%, respectively. There wasno significant difference between two groups(P =0.595, 0.411). After 6 months, there were 5recurrences in the aspirin group, including 3 patients with small PFO(PFO≤1.9mm), but there wasno recurrence in the group closure.Conclusion The difference of recurrence rate between percutaneous PFO closure and aspirinwas not clear. But after percutaneous PFO closure, there was no recurrence. There was greatsignificance of percutaneous PFO closure for treating the patients with small PFO.

Effect of Urinary Kallidinogenase on Acute Cerebral Infarction

MA Cong-Min;WANG Hao.

2010, 5(12):  979-982. 

Asbtract ( )   PDF (2526KB) ( )  

Related Articles | Metrics

Objective To investigate the effect of Urinary Kallidinogenase on acute cerebral infarction.Methods Ninety patients with acute cerebral infarction were randomly divided into twogroups: treatment group with Urinary Kallidinogenase and control group. According toChinese Guidelines for Prevention and Management Cerebrovascular Disease, two groupswere treated with basic therapy; treatment group was administrated intravenous injection ofUrinary Kallidinogenase 0.15PNAU per day for 14 days. The primary efficacy was evaluated byNIHSS(the National Institutes of Health stroke scale, NIHSS), ADL(Activities of daily living,ADL).Results Acute cerebral infarction patients after treatment by Urinary Kallidinogenaseclinical symptoms improved than control group, NIHSS(5.6±3.93 vs 7.71±4.01, P =0.004),ADL(67.18±37.05 vs 54.23±30.25, P =0.015).Conclusion Urinary Kallidinogenase can be effectively treated acute cerebral infarction.

Clinical Analysis of Applying Edaravone Early in Acute Cerebral Infarction

SONG Lai-Jun;LI He-Yong;ZHANG Cai;et al.

2010, 5(12):  983-986. 

Asbtract ( )   PDF (2545KB) ( )  

Related Articles | Metrics

Objective To observe the effects of edaravone on acute cerebral infarction(ACI).Methods Eighty-two acute cerebral infarction patients who were admitted to hospital 6-72h afteronset were randomly divided into treatment group and control group by half. The treatment groupwas given intravenous edaravone by drops(30 mg edaravone were added to 100 ml physiologicalsaline), twice a day for 14 days. The control group was given the same treatments exceptedaravone. Conditions of both groups before and after the treatment were evaluated by clinicalneurological deficit scores and were compared with each other.Results Fourteen days after treatment, clinical neurological deficit scores of the treatment groupwere significant lower than that of the control group(P =0.027), 14d after treatment, both obviouseffects and effects rates of the treatment group were significant higher than that of the controlgroup P =0.016).Conclusion Edaravone is effective on ACI without any serious adverse reaction being observed.

编者按

Stroke Genomics

HUI Ru-Tai;ZHANG Wei-Li

2010, 5(12):  988-987. 

Asbtract ( )   PDF (2405KB) ( )  

Related Articles | Metrics

专题论坛

Advances in the Genetics of Ischemic Stroke

ZHANG Wei-Li;CHEN Yu;HUI Ru-Tai

2010, 5(12):  988-995. 

Asbtract ( )   PDF (2405KB) ( )  

Related Articles | Metrics

Progress in Genetic Research of Ischemic Cerebrovascular Disease

LUO Di;BI Qi

2010, 5(12):  996-1002. 

Asbtract ( )   PDF (1851KB) ( )  

Related Articles | Metrics

病例讨论

Inconsistent Findings of Duplex ultrasound，CTA and DSA In patient with the Subclavian Artery Steal Syndrome: One Case Report

LI Hua;GONG Xi-Ping;XU Xiao-Tong;et al

2010, 5(12):  1003-1006. 

Asbtract ( )   PDF (2262KB) ( )  

Related Articles | Metrics

指南与规范

ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning". A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association

MA Chun;ZHANG Ning;WANG Zhan;et al

2010, 5(12):  1007-1014. 

Asbtract ( )   PDF (1661KB) ( )  

Related Articles | Metrics

综述

Advancement in Integrin AlphaVbeta3 and Ischemic Cerebrovascular Disease Study

MA Xiao-Meng;CHEN Xiao-Hong.

2010, 5(12):  1015-1018. 

Asbtract ( )   PDF (1809KB) ( )  

Related Articles | Metrics

Integrins are important adhesion molecules on cell surface. In the centralnervous system (CNS), they are involved in development and in the adult in areas as diverse assynaptogenesis and activation of microglia, they can also mediate leukocyte extravasation duringCNS inflammation. Recent studies have revealed that integrin alphaVbeta3 (αVβ3) is associatedwith the angiogenesis in many organs including the brain and the hemodynamic changes afterischemic stroke, especially the protection effect of the ischemic tissue by the selective antagonistsof integrin αVβ3 make it a therapeutic target of ischemic stroke and a new interest of these years.